Patent application number | Description | Published |
20100204104 | FUSION PROTEINS CONTAINING TWO TGF-BETA BINDING DOMAINS OF TGF-BETA TYPE II RECEPTOR - The disclosure provides fusion proteins that contain two TGF-β binding domains of TGF-β type II receptor joined to each other by a linker. For example, the C terminus of the first TGF-β binding domain is joined by a short peptide linker (e.g., a 9-glycine linker) to the N terminus of the second TGF-β binding domain. Despite the proximity of the C terminus of the first domain to N terminus of the second domain, such a fusion protein effectively neutralizes TGF-β, in some cases, similarly to anti-TGF-β antibodies. | 08-12-2010 |
20140271676 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION - Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. | 09-18-2014 |
20140294867 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING - The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. | 10-02-2014 |
20140357846 | THYROID STIMULATING HORMONE COMPOSITIONS - Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH. Also described are compositions of mutated Thyroid Stimulating Hormone (TSH) and at least one polyalkylene glycol polymer, wherein the mutated TSH comprises a TSH in which one or more amino acid residues has been substituted with cysteine residue, and the polyalkylene glycol polymer is attached to the mutated TSH at the site of the substituted cysteine residue. Pharmaceutical compositions comprising these TSH compositions and method of treating a thyroid condition in a patient in need thereof, by administering to the patient an effective amount of the pharmaceutical compositions are also described. | 12-04-2014 |
20150079070 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES - Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. | 03-19-2015 |
20150099861 | ANTI ALPHABETATCR ANTIBODY - The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties. | 04-09-2015 |
20160060354 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES - The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. | 03-03-2016 |
Patent application number | Description | Published |
20140107156 | Novel Amino Azaheterocyclic Carboxamides - The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 04-17-2014 |
20140162983 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity - The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase. | 06-12-2014 |
20140243370 | Pyrano[3,2-D][1,3]thiazole as glycosidase inhibitors - Novel compounds of formula (I) | 08-28-2014 |
20140343029 | Novel Imidazole Amines as Modulators of Kinase Activity - The invention provides novel imidazole amine compounds according to Formula (I) and Formula (II) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 11-20-2014 |
20150018318 | Glycosidase inhibitors - Novel compounds of formula (I) | 01-15-2015 |
20150126484 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF KINASE ACTIVITY - The invention provides novel heterocyclic amine compounds according to Formula (I) and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 05-07-2015 |
20150259363 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY - The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase. | 09-17-2015 |
20160000785 | Novel Imidazole Amines as Modulators of Kinase Activity - The invention provides novel imidazole amine compounds according to Formula (I) and Formula (II) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 01-07-2016 |
20160096834 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF - The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors. | 04-07-2016 |
Patent application number | Description | Published |
20080219892 | Guided Mode Resonant Filter Biosensor Using a Linear Grating Surface Structure - Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters. | 09-11-2008 |
20090264314 | Optical Detection of Label-Free Biomolecular Interactions Using Microreplicated Plastic Sensor Elements - Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters. | 10-22-2009 |
20100189338 | SYSTEMS AND METHODS FOR COUNTING CELLS AND BIOMOLECULES - The present invention generally relates to systems and methods for counting biomolecules or cells. In certain embodiments, the invention provides a cell counting or biomolecule counting system including: a covered chamber having a known height and configured to hold a suspension of biomolecules or cells in a sample; at least one fluorescent light source connected to at least one fluorescent light beam narrowing device; a bright-field light source connected to a bright-field light beam narrowing device; a microscope objective; a detection device; a fluorescent filter assembly to allow only excitation light to illuminate the sample and allow only emission light from the sample to be imaged by the detection device; and a movable light shutter to block bright-field light during fluorescent detection. | 07-29-2010 |
20110136152 | SYSTEMS AND METHODS FOR COUNTING CELLS AND BIOMOLECULES - The present invention generally relates to systems and methods for counting biomolecules or cells. In certain embodiments, the invention provides a cell counting or biomolecule counting system including: a covered chamber having a known height and configured to hold a suspension of biomolecules or cells in a sample; at least one fluorescent light source connected to at least one fluorescent light beam narrowing device; a bright-field light source connected to a bright-field light beam narrowing device; a microscope objective; a detection device; a fluorescent filter assembly to allow only excitation light to illuminate the sample and allow only emission light from the sample to be imaged by the detection device; and a movable light shutter to block bright-field light during fluorescent detection. | 06-09-2011 |
20110201132 | Optical Detection of Label-Free Biomolecular Interactions using Microreplicated Plastic - Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters. | 08-18-2011 |
20110237464 | Guided Mode Resonant Filter Biosensor Using a Linear Grating Surface Structure - Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters. | 09-29-2011 |
20130336567 | INTERNAL FOCUS REFERENCE BEADS FOR IMAGING CYTOMETRY - The invention generally relates to analytical and monitoring systems useful for analyzing and measuring cells and biological samples. More particularly, the invention provides systems and methods for internal calibration and focus reference for cytometry imaging. | 12-19-2013 |
20140347463 | SYSTEMS AND METHODS FOR COUNTING CELLS AND BIOMOLECULES - The present invention generally relates to systems and methods for counting biomolecules or cells. In certain embodiments, the invention provides a cell counting or biomolecule counting system including: a covered chamber having a known height and configured to hold a suspension of biomolecules or cells in a sample; at least one fluorescent light source connected to at least one fluorescent light beam narrowing device; a bright-field light source connected to a bright-field light beam narrowing device; a microscope objective; a detection device; a fluorescent filter assembly to allow only excitation light to illuminate the sample and allow only emission light from the sample to be imaged by the detection device; and a movable light shutter to block bright-field light during fluorescent detection. | 11-27-2014 |
20150183153 | CELL COUNTING AND SAMPLE CHAMBER AND METHODS OF FABRICATION - The invention generally relates to analytical and monitoring systems useful for analyzing and measuring cells and biological sample. More particularly, the invention relates to a unique cell counting chamber, e.g., a thin gap fluidic cell chamber for both bright field and fluorescent imaging of bacteria or parasites, and methods for making the same. | 07-02-2015 |
20150232906 | AUTOMATED YEAST BUDDING MEASUREMENT - The invention generally relates to analyzing yeast viability and reproduction rate of yeasts. More particularly, the invention relates to efficient and effective methods and compositions for accessing and measuring budding percentages, viability and concentration of yeast cells. | 08-20-2015 |
20160025710 | INTERNAL FOCUS REFERENCE BEADS FOR IMAGING CYTOMETRY - The invention generally relates to analytical and monitoring systems useful for analyzing and measuring cells and biological samples. More particularly, the invention provides systems and methods for internal calibration and focus reference for cytometry imaging. | 01-28-2016 |
Patent application number | Description | Published |
20090041746 | Combination therapy with IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed. | 02-12-2009 |
20090130084 | Tagged IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed. | 05-21-2009 |
20090317381 | CLEARANCE OF ABNORMAL IGA1 IN IGA1 DEPOSITION DISEASES - The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof. | 12-24-2009 |
20100015044 | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases - The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders. | 01-21-2010 |
20120114629 | IGA1 PROTEASE POLYPEPTIDE AGENTS AND USES THEREOF - Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed. | 05-10-2012 |
20130095036 | METHODS AND COMPOSITIONS FOR DIAGNOSIS OF IGA-AND IGM-MEDIATED KIDNEY DISEASES - The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders. | 04-18-2013 |
Patent application number | Description | Published |
20130131589 | INJECTION DEVICE HAVING AN ANGLED TIP PORTION - In one embodiment, the handheld injection device includes a first housing having a first axis and a second housing having a second axis. In one embodiment, the second housing is configured to support a needle. In one embodiment, the first axis and a second axis form an adjustable angle between about 180 degrees and about 90 degrees. | 05-23-2013 |
20130131632 | INJECTION DEVICE AND METHOD FOR DILUTING AN INJECTABLE FLUID - An injection device enables a user to control the dilution ratio of mixed injectable fluid. In one embodiment, the injection device includes a drive unit configured to apply extrusion forces to fluids. In one embodiment, the injection device produces the mixed injectable fluid based on a selected dilution ratio. In one embodiment, the injection device produces the mixed injectable fluid based on selected injection rates. | 05-23-2013 |
20130131633 | MODULAR INJECTION SYSTEM AND METHOD FOR DILUTING AN INJECTABLE FLUID - A modular injection system enables a user to control the dilution ratio of mixed injectable fluid. In one embodiment, modular injection system includes a handheld injection device operatively connected to a separate control device. In one embodiment, the control device includes a drive unit configured to apply extrusion forces to fluids. In another embodiment, the handheld injection device includes the drive unit. In one embodiment, the modular injection system produces the mixed injectable fluid based on a selected dilution ratio. In one embodiment, the modular injection system produces the mixed injectable fluid based on selected injection rates. | 05-23-2013 |
20130274670 | MODULAR INJECTION DEVICE - A modular injection device for administration of dermal filler compositions is provided. The injection device may include a handheld injector unit including a drive unit, the drive unit configured to apply an extrusion force to a fluid; a control unit remote from the injector unit, the control unit configured to control the drive unit; and a cable configured to connect the control unit to the injector unit. | 10-17-2013 |
20140066845 | INJECTION DEVICE HAVING AN ANGLED TIP PORTION - In one embodiment, the handheld injection device includes a first housing having a first axis and a second housing having a second axis. In one embodiment, the second housing is configured to support a needle. In one embodiment, the first axis and a second axis form an adjustable angle between about 180 degrees and about 90 degrees. | 03-06-2014 |
Patent application number | Description | Published |
20140185282 | METHODS AND APPARATUS FOR TRANSPARENT DISPLAY USING SCATTERING NANOPARTICLES - Transparent displays enable many useful applications, including heads-up displays for cars and aircraft as well as displays on eyeglasses and glass windows. Unfortunately, transparent displays made of organic light-emitting diodes are typically expensive and opaque. Heads-up displays often require fixed light sources and have limited viewing angles. And transparent displays that use frequency conversion are typically energy inefficient. Conversely, the present transparent displays operate by scattering visible light from resonant nanoparticles with narrowband scattering cross sections and small absorption cross sections. More specifically, projecting an image onto a transparent screen doped with nanoparticles that selectively scatter light at the image wavelength(s) yields an image on the screen visible to an observer. Because the nanoparticles scatter light at only certain wavelengths, the screen is practically transparent under ambient light. Exemplary transparent scattering displays can be simple, inexpensive, scalable to large sizes, viewable over wide angular ranges, energy efficient, and transparent simultaneously. | 07-03-2014 |
20140185284 | METHODS AND APPARATUS FOR TRANSPARENT DISPLAY USING UP-CONVERTING NANOPARTICLES - Disclosed herein are transparent color displays with nanoparticles made with nonlinear materials and/or designed to exhibit optical resonances. These nanoparticles are embedded in or hosted on a transparent substrate, such as a flexible piece of clear plastic or acrylic. Illuminating the nanoparticles with invisible light (e.g., infrared or ultraviolet light) causes them to emit visible light. For example, a rare-earth doped nanoparticle may emit visible light when illuminated simultaneoulsy with a first infrared beam at a first wavelength λ | 07-03-2014 |
Patent application number | Description | Published |
20090142806 | INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR - The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling. | 06-04-2009 |
20110033451 | INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFOR - The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling. | 02-10-2011 |